EICHORPublic-registry site landscape for NCT07709000, “A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)”, a Chronic Lymphocytic Leukaemia study sponsored by Merck Sharp & Dohme LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07709000 (registry record) |
| Study title | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) |
| Official title | A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies |
| Sponsor | Merck Sharp & Dohme LLC |
| Condition(s) | Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Hematologic Malignancies |
| Phase | PHASE2 |
| Listed sites | 0 |
| Intervention(s) | MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine), Dexamethasone, Tocilizumab, Tocilizumab biosimilar, Siltuximab |
Patient-friendly overview of this study: eichor.com/study/NCT07709000.
Eichor generates a preliminary site-risk snapshot for NCT07709000 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Chronic Lymphocytic Leukaemia trials
More from Merck Sharp & Dohme LLC
← Eichor home · All tracked trials · Chronic Lymphocytic Leukaemia studies · Weekly briefs
